Skip to main content

ORAGENICS INC

For the period ended Mar 31, 2026. Filed May 8, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31,
20262025
Cash flows from operating activities:
Net loss$(2,201,243)$(2,216,993)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and closing costs-192,859
Stock-based compensation expense17,38617,706
Stock-based compensation recapture expense-(86,470)
Common stock issued for services5,000-
Changes in operating assets and liabilities:
Income receivables53,082-
Prepaid expenses and other current assets232,398159,637
Accounts payable and accrued expenses(307,267)(178,829)
Net cash used in operating activities(2,200,644)(2,112,090)
Cash flows from investing activities:
Proceed from sale of short-term investments4,000,000-
Net cash provided by investing activities4,000,000-
Cash flows from financing activities:
Borrowings on short-term notes payable-2,228,563
Payments on short-term notes payable(171,214)(195,565)
Net proceeds from issuance of common stock79,2102,635,330
Net cash (used) provided by financing activities(92,004)4,668,328
Net increase in cash and cash equivalents1,707,3522,556,238
Cash and cash equivalents at beginning of period4,399,726864,840
Cash and cash equivalents at end of period$6,107,078$3,421,078
Supplemental disclosure of cash flow information:
Interest paid$3,727$6,268
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.